← Leaderboards
Mance E. Buttram
Nova Southeastern University
$521,338
Attributed
$521,338
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $274.5K · FY2017–23$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$521,338 · 2
By mechanism
R21$412,363 · 1
R03$108,975 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Label”
- Carina Remgsamai-Nhe · Fisher Bioservices, Inc.$46,852,833
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$27,332,352
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- James Dale Berry · Brigham And Women'S Hospital$15,344,018
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Andrew S Huhn · Johns Hopkins University$12,205,195
Research focus
LabelOpioidInterviewEpilepsyNational Institute Of Drug AbuseNeuralgiaGamma-Aminobutyric AcidInnovationEcologyEpidemiologyMethodologyMotivationCharacteristicsBehavioralAnalogGabapentinCommunitiesHealth KnowledgeDecision ModelingBuprenorphineCase StudyDesignEthnographyPharmaceutical Preparations
Grant awards (3)
An Examination of Concomitant Non-Medical Use of Gabapentin and Opioids.$137,885
R21 · FY2023 · DA · contact PI
An Examination of Concomitant Non-Medical Use of Gabapentin and Opioids.$274,478
R21 · FY2022 · DA · contact PI
An Examination of Gabapentin/Pregabalin Initiation, Misuse, and Consequences$108,975
R03 · FY2017 · DA · contact PI